Prevnar and PCV-13 versus Synflorix - waging war at 27th ESPID, Brussels with antibody levels.
Published 23rd June 2009
At the recent European Society For
Pediatric Infectious Diseases, (ESPID) 2009 held in Brussels, it was clear that the battle
between Wyeth's Prevnar franchise and GSK's newly licensed pneumococcal vaccine,
SynflorixTM had reached a new level of intensity. VacZine Analytics diagnoses each
company marketing strategy in pneumococcal vaccines and current reaction.
PREMIUMThis article is available only to selected VacZine Analytics clients or can be purchased for delivery.